Four IP takeaways from Novartis’ $9.7 billion acquisition of The Medicines Company
Over the weekend, Novartis struck one of the largest deals in the biopharma sectors this year, agreeing to pay $9.7 billion for cardiovascular specialist The Medicines Company
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.